Journal of Clinical Endocrinology & Metabolism, Vol 81, 3244-3248, Copyright © 1996 by Endocrine Society

ARTICLES

Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues

RE Smith, JA Maguire, AN Stein-Oakley, H Sasano, K Takahashi, K Fukushima and ZS Krozowski
Laboratory of Molecular Hypertension, Baker Institute of Medical Research, Alfred Hospital, Prahran, Australia.

The enzyme 11 beta-hydroxysteroid dehydrogenase type II (11 beta HSD2) confers specificity on the renal mineralocorticoid receptor by inactivating glucocorticoids. Mutations in this gene give rise to the syndrome of apparent mineralocorticoid excess, a congenital condition characterized by sodium retention, severe hypertension, and often by growth retardation. It is not known whether 11 beta HSD2 or another enzyme confers specificity in nonrenal sodium transporting epithelia, such as those in the sweat gland, salivary gland, and gastrointestinal tract. We previously have used the HUH23 antibody to localize 11 beta HSD2 in the human kidney, vascular smooth muscle cells, and placenta. In the present study, we have examined a range of human epithelia for the presence of 11 beta HSD2. In the skin, staining was seen in eccrine sweat glands and arterioles, whereas weak HUH23 immunostaining was observed in the epidermis. Staining was absent from sebaceous glands and hair follicles. In the parotid gland, the 11 beta HSD2 enzyme was present in striated and excretory ducts, whereas in the submandibular gland, it was found in striated and interlobular ducts. Acini, adipocytes, and associated tumor tissue did not stain with the HUH23 antibody. In the gastrointestinal tract, HUH23 stained ileal enterocytes, colonic absorptive cells, and epithelial goblet cells, whereas the rectum contained areas of staining and nonstaining absorptive cells. Gastrointestinal structures, such as the lamina propria, Peyer's patch, and goblet cells within the crypts of Lieberkuhn did not stain with the antibody. This study demonstrates the presence of 11 beta HSD2 in nonrenal sodium-transporting epithelia and describes a range of tissues affected in the syndrome of apparent mineralocorticoid excess.

This article has been cited by other articles:

				M. Groschl Current Status of Salivary Hormone Analysis Clin. Chem., November 1, 2008; 54(11): 1759 - 1769. [Abstract] [Full Text] [PDF]

				L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF]

				S. Kidambi, J. M. Kotchen, C. E. Grim, H. Raff, J. Mao, R. J. Singh, and T. A. Kotchen Association of Adrenal Steroids With Hypertension and the Metabolic Syndrome in Blacks Hypertension, March 1, 2007; 49(3): 704 - 711. [Abstract] [Full Text] [PDF]

				L. B. Sher, H. W. Woitge, D. J. Adams, G. A. Gronowicz, Z. Krozowski, J. R. Harrison, and B. E. Kream Transgenic Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Osteoblasts Reveals an Anabolic Role for Endogenous Glucocorticoids in Bone Endocrinology, February 1, 2004; 145(2): 922 - 929. [Abstract] [Full Text] [PDF]

				J. R. Seckl, N. M. Morton, K. E. Chapman, and B. R. Walker Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue Recent Prog. Horm. Res., January 1, 2004; 59(1): 359 - 393. [Abstract] [Full Text]

				S. Diederich, E. Eigendorff, P. Burkhardt, M. Quinkler, C. Bumke-Vogt, M. Rochel, D. Seidelmann, P. Esperling, W. Oelkers, and V. Bahr 11{beta}-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5695 - 5701. [Abstract] [Full Text] [PDF]

				B. E. ORSIDA, Z. S. KROZOWSKI, and E. H. WALTERS Clinical Relevance of Airway 11beta -Hydroxysteroid Dehydrogenase Type II Enzyme in Asthma Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 1010 - 1014. [Abstract] [Full Text] [PDF]

				E. Schoof, M. Girstl, W. Frobenius, M. Kirschbaum, H. G. Dörr, W. Rascher, and J. Dötsch Decreased Gene Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 and 15-Hydroxyprostaglandin Dehydrogenase in Human Placenta of Patients with Preeclampsia J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1313 - 1317. [Abstract] [Full Text]

				G. Hirasawa, H. Sasano, T. Suzuki, J. Takeyama, Y. Muramatu, K. Fukushima, N. Hiwatashi, T. Toyota, H. Nagura, and Z. S. Krozowski 11{beta}-Hydroxysteroid Dehydrogenase Type 2 and Mineralocorticoid Receptor in Human Fetal Development J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1453 - 1458. [Abstract] [Full Text]

				K. Koyama, I. Sasaki, H. Naito, Y. Funayama, K. Fukushima, M. Unno, S. Matsuno, H. Hayashi, and Y. Suzuki Induction of epithelial Na+ channel in rat ileum after proctocolectomy Am J Physiol Gastrointest Liver Physiol, April 1, 1999; 276(4): G975 - G984. [Abstract] [Full Text] [PDF]

				D. Rogoff, Z. Smolenicka, I. Bergadá, G. Vallejo, M. Barontini, J. J. Heinrich, and P. Ferrari The Codon 213 of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene Is a Hot Spot for Mutations in Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4391 - 4393. [Abstract] [Full Text]

				Y. Takeda, S. Inaba, K. Furukawa, and I. Miyamori Renal 11ß-Hydroxysteroid Dehydrogenase in Genetically Salt-Sensitive Hypertensive Rats Hypertension, December 1, 1998; 32(6): 1077 - 1082. [Abstract] [Full Text] [PDF]

				T. Suzuki, H. Sasano, S. Suzuki, G. Hirasawa, J. Takeyama, Y. Muramatsu, F. Date, H. Nagura, and Z. S. Krozowski 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Human Lung: Possible Regulator of Mineralocorticoid Action J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4022 - 4025. [Abstract] [Full Text]

				S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF]

				G. Hirasawa, H. Sasano, K.-i. Takahashi, K. Fukushima, T. Suzuki, N. Hiwatashi, T. Toyota, Z. S. Krozowski, and H. Nagura Colocalization of 11{beta}-Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Epithelia J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3859 - 3863. [Abstract] [Full Text] [PDF]

				R. E. Smith, K. X. Z. Li, R. K. Andrews, and Z. Krozowski Immunohistochemical and Molecular Characterization of the Rat 11{beta}-Hydroxysteroid Dehydrogenase Type II Enzyme Endocrinology, February 1, 1997; 138(2): 540 - 547. [Abstract] [Full Text] [PDF]